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ABSTRACT
The tetraspanin CD81 is induced in the mesolimbic dopaminergic pathway 
after cocaine administration. To further investigate its role, a regulatable 
lentivirus (Lenti-CD81), bearing the CD81 gene under the control of a 
tetracycline inducible promoter, and lentiviruses expressing shRNA targeted 
against CD81 (Lenti-CD81-shRNAs) have been prepared. Infection of 
HEK293T cells in vitro with Lenti-CD81-shRNAs resulted in 96.5% gene 
silencing (from qRT-PCR and immunocytochemistry). In vivo delivery of 
Lenti-CD81-shRNA into the nucleus accumbens (NAcc) or the ventral 
tegmental area (VTA) resulted in 91.3% and 94% silencing of endogenous 
CD81 respectively. Stereotaxic injection of Lenti-CD81 into these regions, 
resulting in CD81 overexpression, induced a 4 to 5-fold increase in locomotor 
activity after chronic cocaine administration, which returned to basal levels 
when Lenti-CD81-shRNA had been co-injected or when CD81-expression 
was blocked by doxycycline. Furthermore silencing endogenous CD81 in vivo
resulted in a significant decrease in locomotor activity over controls, again 
suppressing cocaine-induced behaviour.
Key Words: siRNA, Cocaine, Addiction, Lentivirus, in vivo gene Transfer, 
Behaviour, CD81, Plasticity, gene knock-down 
Running title: "SILENCING CD81 SUPPRESSES BEHAVIOURAL 
CHANGES IN CHRONIC COCAINE ADMINISTRATION"
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INTRODUCTION
Administration of drugs of abuse induces strong molecular adaptations and 
plasticity within the mesolimbic dopamine (DA) system, a pathway essential 
for reward seeking behaviour. These adaptations underlie a complex 
rewiring of neural circuitry that results in the behaviours associated with 
addiction (Nestler 2000, Robinson and Berridge 1993). Addictive drugs 
(cocaine and amphetamines), depressants (ethanol) and opiate narcotics 
(heroin and morphine) are powerful reinforcers and produce their rewarding 
effects of euphoria or pleasure through an interaction with the mesolimbic 
DA system (Nestler 2000). Little is known about the specific targets involved 
in this neuroadaptation process, but it has been suggested that cocaine and 
other drugs of abuse may alter the morphology of neuronal dendrites and 
spines, the primary site of excitatory synapses in the brain, by means of 
inducing expression changes of surface molecules (Nestler 2000, Yue et al. 
2002). Complex changes in expression of a number of surface axon guidance 
molecules have been observed upon cocaine administration, which may 
underlie important neuroplastic changes in the reward- and memory-related 
brain centres following drug action (Bahi and Dreyer, unpublished 
observation). Local expression changes of these cues may mediate plasticity 
and cytoskeleton rearrangement through mechanisms similar to synaptic 
targeting during development. In addition strong induction of a surface 
tetraspanin protein involved in cell adhesion, CD81, has been described 
(Michna et al. 2001, Halladay et al. 2000, Brenz-Verca et al. 2001). Using a 
regulatable lentivirus bearing the rat CD81 gene under the control of a 
tetracycline-inducible system, previous studies have shown that CD81
expression in the mesolimbic dopaminergic pathway contributes significantly 
to behavioural changes associated with chronic cocaine administration 
(Brenz-Verca et al. 2001). Overexpression of CD81 in this pathway induces a 4 
to 5 fold increase in locomotor activity, which can be reversed to normal in 
the same animal fed doxycycline. 
In this study we further characterized the role of CD81 in drug-induced 
behavioural changes. Cocaine-induced expression changes of CD81 were 
assessed under different protocols of drug administration. Lentiviruses 
expressing shRNA targeted against different regions of the CD81 mRNA 
were developed and used for silencing endogenous CD81 or overexpressed 
CD81 in vivo within the mesolimbic dopaminergic pathway. We demonstrate 
that stereotaxic injection of shRNA-expressing lentiviruses into the nucleus 
accumbens or into the ventral tegmental area results in 93-95% down-
regulation of CD81 in these regions, and this effect is associated with 
suppression of cocaine-induced behavioural changes. 
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MATERIAL AND METHODS 
1. Animal handling and drug administration 
a.- Animal Handling: Animals used in this experiment were male 
Wistar rats weighing 225-250 g (BRL, Fillinsdorf, Switzerland). All animal 
experiments were carried out in accordance with the guidelines and 
regulations for Animal Experimentation, BAG, Bern, Switzerland. Animals
were housed in trios in clear plastic cages with wire grid lids and kept in the 
animal facility maintained on a 12-h light: 12-h dark cycle (lights off at 7:00 
am). Access to food and water was unrestricted.  
b.- Drug administration Protocols: Three different protocols for Drug 
administration were used, as described in Figure 1. Acute Paradigm: Animals
(n=6) were i.p. injected once with 15 mg/kg cocaine-HCl (Sigma Chemical 
Co., Switzerland). Chronic Paradigm: Animals (n=6) were i.p. injected daily 
with 15 mg/kg cocaine-HCl for a period of 15 days. Binge Paradigm:
Animals (n=6) were i.p. injected with 30 mg/kg cocaine-HCl every 2 h for 4 
injections.
In these three protocols control animals received 0.9 % saline i.p. injection 
instead of drug. 24 h after the last injection, animals were sacrificed by 
decapitation and the brain areas were dissected out and used for isolation of 
total RNA, using RiboPure Kit (Ambion, UK) followed by RNA amplification 
according to previous publications (Bahi et al. 2004, Bahi and Dreyer 2004).
c.- RNA Extraction: After sacrifice, brain regions were dissected out 
(NAcc and VTA), and total RNA was extracted using RiboPure Kit (Ambion, 
UK) including an RNase-free DNase step according to the manufacturer’s 
protocol. Briefly, 1 ml of RNAwiz was added to 50 mg of tissue, 
homogenized with a Polytron homogenizer, vortexed for 30 s and incubated 
at room temperature for 5 min. Residual protein was removed by the 
addition of 0.2 ml chloroform, mixing for 30 s, incubation at room 
temperature for 5 min, vortexing for 30 s, and centrifugation for 15 min at 
12000 g and room temperature. The aqueous phase was precipitated with 0.5 
ml of absolute ethanol, filtered over a column and washed by centrifugation. 
The total RNA was then eluted with 0.1 ml of DEPC-treated water, incubated 
at 60 °C for 10 min and stored at –80 °C. RNA was quantified by 
spectrophotometry and its integrity verified by agarose gel electrophoresis 
and visualized with ethidium bromide staining. 
2. Lentivirus Construction 
a.- Lenti-CD81 and Lenti-GFP lentiviruses: The CD81 gene (GenBank 
accession no. NM_013087) was amplified by reverse transcription. Briefly, 2 
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Pg of total RNA (prepared from rat NAcc of cocaine-treated animals) were 
added to 1 Pg Oligo-(dT)12-18, 2 Pl of dNTP Mix at 10 mM each and made up 
to 12 Pl with RNase free-water. These components were mixed and heated at 
65 °C for 5 min then kept on ice. To the mixture 4 Pl of 5 x First Strand Buffer 
was added, followed by 2 Pl 0.1 M DTT, 10 U RNAsin (Invitrogen,  
Switzerland), 1 Pl 200 U/Pl Superscript II RNaseH- Reverse Transcriptase. 
The mixture was incubated at 42 °C for 3 h. To remove RNA-DNA hybrids, 2 
U RNase H were added and incubated at 37 °C for 30 min. The cDNA was 
then PCR amplified and 6His-tagged with the two following primers: CGC 
GGA TCC GCG ATG GGG TGG AGG GCT GC as forward primer and CCG 
CTC GAG CGG TTA ATG ATG ATG ATG ATG ATG GTA CAC GGA GCT 
GTT CCG G as reverse primer. The forward primer contains a BamHI
(Biolabs, Switzerland) restriction site followed by the 5’ Rat CD81 cDNA 
specific sequence; the reverse primer contains the 3’ Rat CD81 cDNA specific 
sequence, a 6His-Tag, a stop codon and an XhoI (Biolabs, Switzerland) 
restriction site. 
The PCR product was digested with BamHI and XhoI and cloned into similar 
sites in pTK431 (figure 2). The pTK431 is a self-inactivating (SIN) HIV-1 
vector, which contains the entire tet-off inducible system, the cPPT and the 
woodchuck hepatitis virus post-transcriptional regulatory element (WPRE). It 
was generated by ligating a BglII/BamHI DNA fragment containing the 
tetracycline-regulated transactivator tTA (5’) and the tetracycline inducible 
promoter (3’) into a BamHI site downstream to a CMV promoter in a SIN 
HIV-1 vector. A control vector construct, pTK433, in which GFP expression is 
regulated by a tetracycline inducible promoter, was generated by cloning a 
BamH I/Bgl II DNA fragment containing the GFP gene into a BamHI site in 
pTK431. All plasmids were CsCl2 purified. 
b.- Construction of Lenti-CD81-shRNAs: To silence CD81 expression in
vitro and in vivo, 5 targets were designed according to the CD81 mRNA 
sequence (GenBank accession no. NM_013087). The following targets within 
the CD81 sequence were selected (Figure 2), based on Hannon’s design 
criterion (http://katahdin.cshl.org:9331/RNAi/html/rnai.html): 1st target: 
907 – 927, 2nd target: 290 – 317, 3rd target: 907 – 927 (with an extra Cytosine 
compared to the 1st target), 4th target: 848 – 866, 5th target: 676 – 696. To each 
oligo, an Xho I restriction site was 3’ added. Using the pSilencer 1.0-U6 
(Ambion, UK) as a template and a U6 promoter specific forward primer 
containing BamH I restriction site GCGGATCCCGCTCTAGAACTAGTGC, 
each shRNA target was added to the mouse U6 promoter by PCR (each target 
contains a 3’ specific U6 promoter specific primer). The PCR conditions were 
highly drastic to avoid mutations within the targets. The following PCR 
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program was performed: 120 s at 94 °C (initial denaturation) followed by 94° 
C – 45 s, 64 °C – 45 s and 72 °C – 45 s repeated 35 cycles. The PCR reaction 
contains 4% dimethyl sulfoxide (Sigma, Switzerland). The PCR product was 
digested with BamHI and XhoI, cloned into similar sites in pTK431, and 
sequenced to verify the integrity of each construct. 
c.- Lentivirus Production The vector plasmids (either pTK431-CD81-
6His, pTK433-GFP or pTK431-U6-shRNAs), together with the packaging 
construct plasmid p¨NRF and the envelope plasmid pMDG-VSVG were co-
transfected into HEK293T cells to produce the viral particles (Bahi et al. 2004, 
Naldini et al. 1996). The viral titres were determined by p24 antigen 
measurements (KPL, USA). For the in vivo experiments, the different viral 
stocks matched for viral particle content were used at 0.4 mg/ml of p24. 
d.- In vitro Assays: The efficiency of the Lenti-CD81-shRNAs was 
tested in vitro by infection of HEK293T cells. The day before the infection, 3 x 
105 HEK293T cells were plated per well in six-well plates. The next day, 3 Pl
from lentivirus stocks were added with Polybrene (Sigma, Switzerland, at 10 
Pg/ml final concentration), incubated 30 min at room temperature, and the 
cells were plated at 37 °C for 24 h. The next day, the medium was replaced 
with normal growth medium and cells were left for 24 h. One part of the cells 
was used for RT-PCR after total RNA isolation and the remaining part was 
used for immunocytochemistry. 
Real time PCR and CD81 mRNA Quantification: Total RNA was 
extracted from the HEK293T cells using RiboPure Kit (Ambion, UK) 
including a RNase-free DNase step, and stored at –80 °C according to the 
manufacturer’s protocol. RNA was quantified and its integrity verified . First 
strand cDNA was generated from 1Pg of total RNA and Oligo(dT12-18) primer 
with the M-MLV reverse transcription kit (Invitrogen, Switzerland) in a total 
volume of 20 Pl according to the manufacturer’s protocol. To quantify the 
CD81 mRNA level, quantitative real-time PCR was used. Primer sets were 
designed to amplify 100-300-bp products, using PRIMER3 software 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi).
The reverse transcription reaction was amplified (qRT--PCR was performed) 
with the following pairs of oligonucleotides specific for rat CD81, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and E-Actin. CD81:
5’-TGA TCC TGT TTG CCT GTG AG-3’ and 5’-CAG TTG AGC GTC TCA 
TGG AA-3’, GAPDH: 5’-ATG ACT CTA CCC ACG GCA AG-3’ and 5’-CAT 
ACT CAG CAC CAG CAT CAC-3’, E-Actin: 5’- AGC CAT GTA CGT AGC 
CAT CC-3’ and 5’-CTC TCA GCT GTG GTG GTG AA-3’. GAPDH and E-
actin were used as internal controls. The quantification was performed using 
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the real-time PCR iCycler (BioRad, Switzerland). For PCR, 5 Pl cDNA 
preparation, 0.5 PM of forward and reverse primers and 10 Pl of IQ SYBR 
Green Supermix (Biorad, Switzerland) in a total volume of 20 Pl were 
applied. The following PCR program was performed: 3 min at 95 °C (initial 
denaturation); 20 °C/sec temperature transition rate up to 95 °C for 45 sec, 45 
sec 62 °C, repeated for 40 times (amplification). The PCR reaction was 
evaluated by melting curve analysis following the manufacturer’s 
instructions and checking the PCR products on 2 % agarose gel. 
Values for CD81 overexpression were calculated against the signal for 
GAPDH (or E-actin), selected as endogenous, constitutively expressed control 
mRNAs for normalization. No difference was observed whether GAPDH or 
E-actin was used for all normalizations. The levels for NAcc or VTA samples 
from cocaine-injected rats were normalized to the levels for the samples from 
saline-treated animals within the same experiment. PCR amplifications were 
done at least in triplicate from 3-pooled samples isolated from separate pools 
of animals or cells and the PCR cycle number at which each assay target 
reached the threshold detection line was determined (“threshold cycles”, Ct 
value), using the second derivative of the reaction. The Ct of each gene was 
normalized against that of GAPDH (or E-actin). To determine the linearity 
and detection limit of the assay, cDNA samples were amplified for successive 
10-fold dilutions in a series of real-time PCRs, using duplicate assay on each 
dilution, so that the correlation coefficient could be calculated from the 
standard curve of Ct values. Comparisons were made between cocaine and 
saline groups and significance was calculated using two-tailed Student’s t-
test and the level of statistical significance was set at P<0.05. Data were 
expressed as mean ± SEM. The ¨Ct for each candidate was calculated as ¨Ct
= [Ct (candidate) – Ct (GAPDH or E-Actin)]. The relative abundance of each 
target in each protocol can be calculated as the ratio between treated and 
untreated samples (Mühlhauser et al. 2004). 
Immunocytochemistry on HEK293T Cells: after infection cells were 
washed twice with 1 x PBS, fixed with pre-warmed 4 % PFA for 30 min and 
washed again with 1 x PBS buffer. Cells were blocked for non-specific 
binding with 3 % normal goat serum diluted in 1 x PBS for 20 min and 
incubated overnight at 4 °C with mouse histidine tag antibody (MCA1396, 
Serotec) diluted 200 fold in 1 x PBS containing 1 % normal goat serum, 0.1 % 
Triton-X100. Cells were rinsed 3 times with 1 x PBS and incubated with the 
secondary antibody (Texas red-conjugated goat anti-mouse immunoglobulin 
G, Molecular Probes) diluted 1000 times in 1 % normal goat serum, 0.1 % 
Triton-X100 in the dark at room temperature for 3 h. Cells were washed 3 
times with 1 x PBS cover-slipped with a medium containing glycerol in 
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1xPBS (AF1 mounting solution, Citifluor-Ltd). In all cases negative controls 
included omission or substitution of the primary antibody. 
Fluorescence microscopy: Stained cells were observed using a multi-
fluorescence microscope Axioplan 2 imaging; (Zeiss, Germany) with an x63 
objective and photographed using a multi-channel camera (Axiocam, Zeiss, 
Germany) linked to acquisition software (Axiovision system 3.1). The 
fluorophore was detected with the appropriate detecting system (HAL 100). 
Texas red was exited by a 595 nm beam and was detected through a light 
path ranging from 600-660 nm.
Quantification: Cells were photographed with a x40 objective using a 
digital camera (Axiocam, Zeiss) attached to a multi-fluorescence microscope 
(Axioplan2 imaging, Zeiss). Special care was taken to place the frame in the 
same location on each region analyzed for each slide. Within each section, 
frame size was kept constant from slide to slide. The density of CD81-positive 
cells was calculated for each slide using the Scion software. Each image was 
transformed into TIFF format, normalized by subtracting the background. 
Then a semi-automatic cellular density measurement was undertaken by 
calculating total pixel density at a fixed brightness level. Separate exposures 
were made for each section to ensure that density measurements were 
reproducible. The high mean level of pixel intensity correlated to high 
amounts of expression of CD81 in the specific area. To each set of CD81 
immunoreactivity measurements, ANOVA followed by a Scheffe F tests was 
used. All results are expressed as a mean ± SEM. 
3. In-vivo Assays 
a.- Stereotaxic surgery and Injection of the Lentiviral Vector: Before the 
operation, rats were injected with ketamine/xylazine 100 mg/kg, 10 mg/kg, 
i.p.). After 10 min, the surgical field was shaved, cleaned using Hibitane 
solution (0.5 % chlorhexidine gluconate in 70 % Ethanol) and Lacrilube was 
applied to eyes. Animals were placed into a stereotaxic frame (Stoelting, IL). 
Stereotaxic injections were performed using a 5-Pl Hamilton syringe with a 
33-gauge tip needle. The injections were performed in the VTA (anterior –6; 
lateral +/-0.5; ventral -8.2) and the NAcc (anterior +1.4; lateral +/-1.6; ventral 
-6.8) as calculated from bregma and the dura mera. The skin was opened 
with scalpel incision along the midline and 0.2 ml of Mercain (0.25 % 
bupivacaine hydrochloride) was applied to the wound for local analgesia. 
Overlying tissue was blunt dissected with sterile Q-tips to visualize bregma 
and the skull was delicately bored at pre-determined co-ordinates. Heating of 
the skull was reduced by application of sterile 0.9 % saline solution around 
the drilling site. Male Wistar rats were bilaterally injected into the VTA or 
into the NAcc with 4 Pl of concentrated lentiviral stock (co-injection of 2 Pl of 
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Lenti-CD81 or Lenti-GFP together with 2 Pl of Lenti-shRNAs) slowly infused 
at the speed of approximately 0.2 Pl/min. The cannula was then maintained 
in place for a further 5 min after injection and then withdrawn very slowly to 
prevent backflow of solution. The wound site was closed with braided silk 
suture. Rats were then removed from the frame, injected with a mixture of 2.5 
ml of 0.9 % saline solution and Rimadyl (carprofen 2 mg/kg, s.c.) for 
hydratation and pain relief. Lacrilube was re-applied to eyes. The animal was 
returned back to the cage out of the surgery room, kept warm and off 
sawdust (as this can be inhaled by rats not fully conscious). Post-op diet for 3 
days consisted of normal food pellets soaked in water. Rat recovery was 
followed up. 
b.- Drug Treatment and Locomotor Activity measurement: Locomotor
activity was monitored during the dark cycle. One week after surgery, each 
subject was weighed; the animal was brought down from the animal facility 
and placed immediately into the activity-monitoring cage for a 30 min 
baseline without drug. After a 30 min period, the session automatically 
paused and during this interval, each subject received cocaine-HCl (15 
mg/kg, i.p.) and was then placed back into the locomotor activity-monitoring 
cage for 60 min (Bahi et al., 2004). 
Locomotor activity was monitored in MED-OFA-RS cages (MED Associates 
Inc. USA). Animals were placed in a square (43.2 cm x 43.2 cm x 30.5 cm) 
PVC retainer. Activity in the monitor was recorded by photobeam 
interruptions. A ring of 16 sensors, spaced 2.54 cm from each other, measured 
the “X–Y” location of the animal four times per second. The activity monitor 
computed the location of the animal in each of the X and Y dimensions as the 
middle point between the extreme beam interruptions in this dimension. Two 
sets of strips were used for the “X-Y” ambulatory data input while a single 
set was used for the “Z” rearing data. 
Speed was estimated by computing the standard deviation of the distances of 
the data points to their mean within a sliding time window 0.4 s wide, 
constructed around each data point in turn. Box size was defined with 2 
photobeams of X or Y to be broken before a movement was considered 
ambulatory. Starting at time 0, the box was centred on the subject. When the 
animal moved to the outside of the box, it was considered ambulatory and 
the box re-centred on the subject. The subject remained ambulatory until it 
did not leave the last re-centred box in less than the resting delay. The 
travelled-distance was then calculated. Stereotypic counts were defined as 
the total number of beam breaks inside the box. 
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c.- Statistical Evaluation of Behavioural Analysis: the distance 
travelled was summed over each test session and analyzed by means of one-
way analysis of variance (ANOVA), with the data divided into 5-min bins. 
Appropriate post-hoc comparisons were used to compare groups if a 
significant interaction was found (P<0.05). These comparisons were made 
using Fisher’s least significant difference test. Independent Student’s t-tests 
were used when a significant interaction was found. All these analysis were 
performed using SPSS software (Podhorna and Didriksen 2004, Sanchis-
Segura et al. 2004, Okabe and Murphy 2004). The use of standard deviation is 
based on the analysis of the coordinates of the path. This is because 
estimating the speed - measured as travelled distance per min - in a given 
time point ti depends on measuring the coordinates in two time points (e.g. 
the difference between the coordinates at times ti and ti-1).
Within the same group, the means and standard deviations were done on 
measurements performed each day. No significant changes were observed in 
day to day recordings over the same session. The means and the standard 
deviations from all measurements within one session were then calculated 
(using values obtained from subjects of the same group at the same session) 
and plotted (Bahi et al. 2004).
4. Immunohistochemistry
 At the end of the session, animals were sacrificed by decapitation. Rat brains 
were rapidly dissected out, frozen in isopentane upon extraction (at –30 °C 
for 3 min) and kept at –25 °C. Coronal sections were cut at 14 Pm in a cryostat 
(Leitz) and placed on gelatinized glass slides, air–dried at room temperature 
for 20 min and kept at –25 °C until further processing. Antigens were 
localized using the avidin-biotin-peroxidase technique. Slices were fixed in 4 
% PFA for 15 min, washed thrice with 1 x PBS. Endogenous peroxidase 
activity was quenched with 2 % hydrogen peroxide in water  (H2O2) for 40 
min at room temperature. Non-specific binding was blocked for 30 min at RT 
in 1 x PBS containing 1 % bovine serum albumin, 1 % Triton X-100 and 3 % 
normal goat serum. Sections were incubated overnight with mouse anti-
histidine antibody (MCA1396, Serotec, 1:12000) diluted in 1 x PBS containing 
1 % Triton X-100 and 1 % normal goat serum. Sections were then washed 
three times with 1 x PBS and incubated with the biotinylated secondary 
antibody (goat anti-mouse immunoglobulin G, Vector laboratories, 
Burlingame, 1:500) for 45 min at RT. Sections were rinsed three times for 5 
min in 1 x PBS at RT, followed by avidin-biotin complex (Vector laboratories, 
Burlingame) in 1 x PBS  solution. After three rinses in 1 x PBS, all sections 
were developed in 0.025 % 3-3’ diaminobenzidine tetrahydrochloride (DAB) 
plus 0.02 % H2O2 for 10–15 min. Sections were then dehydrated, mounted in 
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permanent medium (Eukitt) and examined with a Zeiss light microscope. 
GFP expressing sections were cover-slipped with AF1 mounting solution 
(Citifluor Ltd), and directly observed using a multi-fluorescence microscope 
Axioplan 2 imaging (Zeiss, Germany) mounted with a multi-channel camera 
Axiocam (Zeiss, Germany) linked to acquisition software Axiovision 3.1 
(Zeiss, Germany). In all cases negative controls included omission or 
substitution of the primary antibody. 
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RESULTS
Cocaine-induced CD81 Expression: 
CD81 was found initially in a screening for genes up-regulated after cocaine 
administration following a “binge” protocol. In order to further characterize 
this observation, up-regulation of CD81 was confirmed in different 
paradigms of drug administration, summarized in figure 1, i.e. acute, binge 
and chronic treatments. The total RNA from the NAcc and the VTA of 
animals treated under the different paradigms (figure 1, n=6) were prepared, 
reverse transcribed and CD81 expression was assessed by means of 
quantitative real-time PCR analysis after normalization against GAPDH, E-
actin and HSP-70 considered as endogenous controls (no difference was 
observed between all normalizations). The results are shown in figure 3. The 
strong up-regulation in these two brain regions observed after binge 
treatment could be confirmed: CD81 displays a 6.2-fold up-regulation in the 
NAcc and a 3.9-fold up-regulation in the VTA, in agreement with previous 
studies (Brenz-Verca et al. 2001). Furthermore, CD81 was also 2.9 to 4.0-fold 
up-regulated after chronic treatment in these regions. On the other hand 
acute treatment induced small, but significant overexpression of CD81, 
yielding a 1.4 fold up-regulation in the VTA and in the NAcc. Subsequent 
studies (locomotor activity monitoring) were then performed according to the 
chronic protocol, but the silencing effect of the endogenous CD81 in the NAcc 
and VTA was followed-up after binge treatment, which induces highest 
expression of endogenous CD81. 
shRNA lentiviruses and in vitro CD81 silencing:
In order to locally knock-down CD81 expression in selected brain areas, 
lentivirus-based RNA interference was used. Five different shRNAs were 
designed, targeted against different regions of the CD81 mRNA, as displayed 
in figure 2 (as described in the “Materials & Methods”, lentivirus construction 
section). Constructs bearing a U6 promoter were inserted into the transfer 
plasmid of the lentivirus system. Lenti-CD81-His6 (Bahi et al. 2004), lenti-GFP 
(Bahi et al. 2004) and lenti-CD81-shRNAs all share the same vector backbone; 
however lenti-CD81-shRNAs are not regulatable due to the presence of the 
U6 promoter. Incorporation of the tetracycline inducible system into the 
lentivirus vectors conferred the ability to control transgene expression in vivo
(Kafri et al 2000, Reiser et al 2000). The tetracycline inducible system is based 
on two components: (a) the tetracycline regulated transactivator (tTA), which 
is a fusion protein of the tet repressor, and the transactivator domain of the 
herpes simplex virus protein VP16; and (b) the inducible promoter, which 
contains a minimal promoter and seven copies of the Tet operon. In the 
absence of tetracycline, the tTA binds and activates the inducible promoter. 
ht
tp
://
do
c.
re
ro
.c
h
13
Binding of tetracycline (or its more potent analogue, doxycycline) to the tTA 
induces conformational changes that render the tTA incapable of binding to 
the Tet operon and thus abolish transgene expression (Haak et al 2004). A 
CMV promoter located in the middle of the vector genome constitutively 
expresses the tTA, while the inducible promoter at the 3’end of the vector 
regulates the expression of the transgene on interest (Kafri et al 2000).
To assess the efficiency of the five different targets at silencing CD81, in vitro
assays were performed in HEK293T cells co-infected with Lenti-CD81. As 
controls, cells co-infected with Lenti-GFP (instead of Lenti-CD81-shRNAs) 
and Lenti-CD81 were used. 48 h after infection, cells were harvested, total 
RNA was extracted and CD81 mRNA measured by means of quantitative RT-
PCR. As shown in figure 4A and 4B, shRNA-3 and -5 induced 88 % and 85 % 
decreases in CD81 mRNA levels, respectively. The other targets, shRNA-1, -2 
and –4, were less efficient at silencing CD81 in vitro, resulting in 62, 56 and 45 
% expression of CD81 mRNA, respectively. However, when all targets were 
co-infected together, CD81 silencing was >96.5 % (figure 4 A and B). It should 
be noted that Lenti-CD81-shRNA3 and Lenti-CD81-shRNA1 target the same 
region of the mRNA, yet differ only very slightly in their sequence: in Lenti-
CD81-shRNA3 one C has been deleted compared to Lenti-CD81-shRNA1. It 
is interesting to observe that this very minor change in the sequence results in 
much more efficient silencing of Lenti-CD81-shRNA3 compared to Lenti-
CD81-shRNA1 and makes it the best among all candidates tested, whereas 
the other may serve as a very good negative control.
Protein expression was also tested by means of immunocytochemistry: cells 
co-transfected with the Lenti-CD81-shRNAs (all targets together) and Lenti-
CD81 display 96-97 % silencing of CD81 (figure 4C and D). For in vivo assays, 
only the two most efficient Lenti-CD81-shRNA’s, i.e. Lenti-CD81-shRNA-3 
and Lenti-CD81-shRNA-5, were used and co-infected. 
In vivo knock down of endogenous CD81: 
To test the in vivo silencing efficiency of the Lenti-CD81-shRNAs, the Lenti-
CD81-shRNA-3 and Lenti-CD81-shRNA-5 were stereotaxically co-injected 
into the NAcc or the VTA of animals (n=6). Control animals were injected 
with Lenti-GFP (instead of Lenti-CD81-shRNAs) into the same areas. 
Endogenous CD81 is expressed at low levels in the rat brain under normal 
conditions, but is strongly induced in the mesolimbic dopaminergic pathway 
upon cocaine administration, especially after a high dose cocaine treatment 
(“binge” protocol, figure 3). Therefore, in order to optimally induce the 
expression of endogenous CD81 in the targeted areas, animals were treated 
according to the “binge” protocol (figure 1, 120 mg/kg cocaine in a single 
day), which strongly promotes CD81 expression in the mesolimbic 
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dopaminergic pathway (figure 3, and Brenz-Verca et al. 2001, Bahi et al. 2004). 
Seven days after surgery, animals were injected with 30 mg/kg of cocaine i.p. 
every 2 h for 4 injections and sacrificed 24 h after the last injection. Control 
animals, i.e. animals treated with Lenti-GFP, received cocaine injections 
under the same schedule. After sacrifice, the brain regions of interest were 
dissected out and the total RNA prepared. Quantitative Real Time-PCR was 
then performed on cDNA from these RNA preparations, and the mRNA 
levels were quantified and normalized against GAPDH considered as an 
endogenous control (normalization against E-actin and HSP-70 were done 
also and give practically the same results, data not shown). As shown in 
figure 5, co-injection of Lenti-CD81-shRNA-3 and –5 together resulted in 
91.3% and 94% decrease in endogenous CD81 mRNA levels in the VTA and 
in the NAcc, respectively, compared to CD81 mRNA levels observed in 
control animals (infected with Lenti-GFP in the same brain areas). 
Behavioural Changes induced upon CD81 expression:
Four groups of animals (n=6) were used for assessing the effects of Lenti-
CD81-shRNAs on cocaine-induced behavioural changes. One group of 
animals was injected with the doxycycline-regulatable Lenti-CD81 into the 
NAcc. After surgery, animals were fed without doxycycline (normal water), 
enabling full expression of CD81 in the targeted area. Seven days after 
surgery the animals were receiving chronic cocaine i.p. (15 mg/kg) and the 
locomotor activity was monitored daily after drug administration. As shown 
in figure 6A (Session A (left panels), after cocaine administration a strong 
raise in locomotor activity was observed with a peak at 19,192 mm/min 
observed 15 min after drug administration, in agreement with previous 
observations (Bahi et al. 2004). After five days the same animals were fed 
doxycycline in the drinking water (inducing down-regulation of lentivirus-
expressed CD81 in the targeted area), and their behaviour upon chronic 
cocaine administration was further evaluated for five consecutive days. 
Under these conditions locomotor activity dropped back almost to control 
levels after cocaine injection, with a peak at 6,302 mm/min (figure 6A, 
Session B). Five days later, doxycycline was finally removed (enabling re-
expression of lentivirus-mediated CD81 in the NAcc). This restored 
locomotor activity back to its initial levels, with a peak at 18,852 mm/min at 
45 min (figure 6A, Session C). The difference between peaks in both sessions 
A and C was not significant.  
Another set of control animals was infected with the doxycycline-regulatable 
control lentivirus, Lenti-GFP, into the same brain area (NAcc) and submitted 
to the same cycles of chronic drug administration, with regimens consisting 
initially of 5 days in absence of doxycycline (Session A), followed by five 
days under doxycycline (Session B) and finally five days under removal of 
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the doxycycline (Session C). As shown in figure 6A (rightest panels), cocaine 
administration induced a small raise in locomotor activity, with a peak of 
3,780 mm/min at 40 min. However this behaviour was independent of GFP-
expression. Another control group consisting of naive animals, not treated 
with lentivirus, behaved like the group infected with Lenti-GFP when 
receiving the same doses of cocaine (data not shown). The observed 
locomotor activity was not significantly affected by the doxycycline regimen: 
locomotor activity displayed a peak at 3,647 mm/min at 40 min in the 
presence of doxycycline and 3,888 mm/min when doxycycline was again 
removed.
A third group of animals was treated by co-injection of the regulatable Lenti-
CD81 (same concentration as the first group) together with (non-regulatable) 
Lenti-CD81-shRNA-3 and Lenti-CD81-shRNA-5. Animals were then 
submitted to the same regimen and drug treatment as the other groups: seven 
days after surgery, chronic cocaine administration was initiated in the 
absence of doxycycline, i.e. under conditions where lentivirus-mediated 
CD81 expression was achieved. As shown in figure 6A (middle left panels), 
in the absence of doxycycline, locomotor activity was low, with a peak at 
5,105 mm/min at 45 min, corresponding to only 8 % of the locomotor activity 
observed under the same conditions in the absence of silencing Lenti-CD81-
shRNAs; ie almost 92 % of the behavioural effect was abolished with the 
Lenti-CD81-shRNAs when basic locomotor activity was subtracted (Lenti-
GFP infected animals) (session A, left panel). After 5 days, doxycycline was 
added to the regimen (session B), inducing down-regulation of exogenous, 
lentivirus-mediated CD81 expression, but not of lentivirus-mediated shRNA 
because Lenti-CD81-shRNAs are not regulated by doxycycline (due to the 
presence of two distinct promoters in the lentivirus construct). As shown in 
the panel, locomotor activity decreased further under these conditions, and 
reached a peak of 3,100 at 45 min, i.e. the locomotor activity under these 
conditions was even significantly lower (40 %) than in the corresponding 
GFP-treated animals. This low activity most probably corresponds to 
silencing of the endogenous CD81, which, in the absence of silencing shRNAs 
(first two groups of animals), would be strongly induced under these 
conditions (see figure 3, chronic treatment). As a matter of fact, the level of 
exogenous CD81 was decreased drastically by doxycycline. Upon removal of 
doxycycline five days later (session C), this group of animals displays no 
significant raise in locomotor activity: under these conditions lentivirus-
mediated CD81 overexpression would be restored, but at the same time it 
was clearly silenced by the expression of Lenti-shRNAs. 
A fourth group of animals was treated by co-injection of the Lenti-CD81-
shRNA-3 and Lenti-CD81-shRNA-5 (same doses as previous group) together 
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with Lenti-GFP and submitted to the same cycles of regimen and drug 
administration (figure 6A, middle right panels). This control group was 
aimed at testing the effects of Lenti-CD81-shRNAs on expression of the 
endogenous protein in absence of exogenous CD81. Under all conditions and 
regimens, locomotor activity was slightly but significantly lower than the 
activity observed with the second group of (control) animals, which were 
treated with Lenti-CD81 only. In the initial 5-day cycle (i.e. in absence of 
doxycycline, session A), a peak of 3,347 mm/min was observed, significantly 
lower (p<0.08) than in the second group under the same conditions. In the 
presence of doxycycline (session B), a peak of 3,103 mm/min was observed, 
identical to the level reached by the third group of animals (3,100 mm/min) 
but significantly lower (p<0.08) than the control group, which had been 
injected with Lenti-GFP only (3,647 mm/min). Finally when doxycycline was 
removed (session C), these animals displayed no change in locomotor activity 
compared to the third group (3,424 mm/min versus 3,209 mm/min, 
respectively), but the observed activity was still significantly lower than the 
second group (treated with Lenti-GFP only) under the same conditions (3,888 
mm/min). This decrease in activity over the control groups again should be 
related to silencing of endogenous CD81 and further confirms the previous 
observations.
A similar series of experiments was conducted on four groups of animals 
where the viruses were injected into the VTA, instead of the NAcc. The same 
results were observed, as shown in figure 6B. Cocaine-induced locomotor 
activity upon CD81 expression was lower, with a peak at 13,343 mm/min at 
45 min, compared to 19,192 mm/min when CD81 was expressed in the NAcc. 
However, the decreases in locomotor activity in the presence of the Lenti-
CD81-shRNAs were of the very same proportion under all conditions.
Figures 6C and 6D summarizes the changes observed under these conditions 
at peak activity (40 min after drug injection). As shown, under all conditions 
statistically significant differences (p<0.08) were observed between the 
second group (corresponding to silencing endogenous CD81) and the fourth 
group, i.e. where endogenous CD81 was not silenced in these brain areas. 
Because of low levels of endogenous CD81, differences are small but 
nevertheless significant. Together these data show that lentivirus-mediated 
gene silencing of CD81 expression in the mesolimbic dopaminergic pathway 
resulted in suppression of CD81-induced locomotor activity.   
Expression of CD81 was assessed by immunohistochemistry at the end of 
each session, as shown in figure 7. Clearly lentivirus-mediated gene delivery 
with Lenti-CD81 results in very local gene expression in the NAcc or the VTA 
(figure 7A and 7C, top panels). This expression is supressed with doxycycline 
(Figure 7B and 7D, top panels), as expected. In addition when the CD81 
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silencers viruses, Lenti-CD81-shRNAs, are co-injected with Lenti-CD81 
(Figure 7A-7D, lower panels), full gene knock down also results in 
suppression of protein expression in the infected brain area. These controls 
further establish the good functionality of the tools developed in this study. 
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DISCUSSION
For the present study we developed lentiviral-mediated delivery of shRNA in
vivo and demonstrate the efficacy of this approach to locally reduce target 
CD81 expression in vivo. The method has been validated by several means, 
including in vitro assays and evaluation of behavioural changes in vivo. The 
ability of lentiviral vectors to transduce cells efficiently in vivo coupled with 
the efficacy of virally expressed shRNA shown here, extends the application 
of shRNA to viral-based therapies and in vivo targeting experiments that aim 
to define the function of specific genes.
In vivo Delivery of shRNAs in the Brain 
The efficiency of shRNA at silencing gene expression in vivo centres around 
four primary challenges responsible for the downfall of the approach: in vivo
delivery of shRNA, choice of the appropriate target, stability of the shRNA, 
long term expression of the shRNA (Shi 2004). So far, very few studies have 
reported the use of shRNA in vivo, because of these limitations. Its efficacy 
has been demonstrated in vivo in inhibition of expression of some disease-
related targets: the vascular endothelial growth factor (Usman 2004, Filleur et
al. 2003), caspase-8 (Zender et al. 2003), hepatitis B (McCaffrey et al. 2003) and 
C viruses (Usman 2004, Yokota et al. 2003), E-catenin (Verma et al. 2003), TNF-
D, AGRP (Makimura et al. 2002), E-
glucuronidase (Davidson and Paulson 2004), the receptor tyrosine kinase 
MuSK of neuromuscular junction (Kong et al. 2003) and the endogenous Fas 
gene expressed in adult mouse liver (Song et al. 2003). Delivery has been cited 
as one of the most important barriers to RNA-based therapy (Davidson and 
Paulson 2004). The effectiveness of siRNA is often lost when siRNAs are 
injected into animals, due to rapid clearance and degradation (Usman 2004). 
Recently, several breakthroughs have highlighted viruses as excellent 
vehicles for siRNA delivery (Zhang et al. 2003, Devroe and Silver 2004). 
Retroviruses, the transgene-delivery vector of choice for many experimental 
gene therapy studies, have been engineered to deliver and stably express 
therapeutic siRNA within cells, both in vitro and in vivo (Rubinson et al. 2003, 
Jain 2004). Delivery of siRNAs into the central nervous system (CNS) adds an 
additional challenge. RNAi targeting neurological disease genes can be 
accomplished in vitro, with profound effects on cellular phenotypes, but the 
difficult challenge lies in the translation of this technology to the CNS, 
primarily the problem of delivery to the brain. Therefore there has been no 
study so far relating the efficiency of siRNA in treating pathophysiological 
disorders or mood disorders in vivo and studies so far are limited to target 
evaluation in vitro (Kong et al. 2003, Beckman et al. 2003). Recently another 
study also successfully demonstrated for the first time the use of this 
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technology in assessing pathophysiological conditions in the CNS, by 
intrathecal administration of shRNAs to down regulate P2X3 gene expression 
in vivo, and evaluation of the roles of putative pain genes in pain models 
(Dorn et al. 2004).
Our study was designed to overcome two additional difficulties: on the one 
hand, we aimed at silencing a gene very locally in the CNS, to prevent effects 
in unrelated areas, and on the other hand long-term expression of the shRNA 
was desired to assess behavioural changes over several weeks. With this 
respect, delivery of retroviral self-inactivating lentiviruses is ideal, as they 
transfect post-mitotic cells, including neurons, with permanent incorporation 
of the elements encoding for shRNA into the host genome, and will not 
spread away from the injection site, thus yielding to a very localised effect. 
This enabled the use of shRNA in combination to behavioural evaluation to 
assess changes induced upon gene expression in vivo.
Another challenge in the methodolgy lies in the design of shRNA. It is crucial 
that siRNA must not cause any effects in vivo other than those related to the 
knockdown of the target gene. This issue is particularly important in 
therapeutic applications where unwanted side effects would be undesirable 
(Shi 2004). Although the actual substrate specificity of individual siRNAs 
appears to be very high (Brummelkamp et al. 2002), recent studies indicate 
that siRNAs can tolerate single mutations located in the centre of the 
molecule, and up to four mutations are necessary for complete inactivation 
(Holen et al. 2002, Jacque et al. 2002). Thus, some mismatches can be tolerated, 
in particular noncanonical base pairs that are frequently found in double-
stranded microRNA precursors (Mourelatos et al. 2002). In the present study, 
we found however that a single mutation in shRNA greatly affects its 
activity, as shown by the efficacy of shRNA3 compared to shRNA1. A further 
complication in the method has been pointed out from global gene 
expression using microarray technology to examine the specificity of siRNAs, 
with the interesting finding that a large number of non-targeted genes 
containing as few as 11 continuous nucleotides with identity to the siRNA 
may be affected by siRNA treatment (Jackson et al. 2003). Using the same 
approach, the overall cellular effects of siRNAs on transcription levels has 
been investigated (Semizarov et al. 2003). Similar assays of validation remain 
to be performed on our targets. 
Application of lentiviral-based shRNA delivery in vivo to assess the 
putative role of CD81 in addiction
In this study we also confirm earlier observations establishing that the 
tetraspanin CD81 is induced in the mesolimbic dopaminergic pathway after 
cocaine administration. CD81 expression causes behavioural changes 
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associated with drug intake, which can be reversed by means of local gene 
knock-down. Applying our strategy of lentiviral-based delivery of shRNA in
vivo to reduce CD81 expression in the mesolimbic dopaminergic pathway, we 
were able to demonstrate that this effect significantly reduces drug-induced 
locomotor activity in the rat. Stereotaxic injection of a regulatable Lenti-CD81 
into the NAcc or the VTA, resulting in CD81 overexpression in these regions, 
induced a 4 to 5-fold increase in locomotor activity after chronic cocaine 
administration, which returned to basal activity when Lenti-CD81-shRNA 
had been co-injected or when CD81-expression was blocked by doxycycline. 
Furthermore in vivo delivery of Lenti-CD81-shRNA into these areas resulted 
in >90 % silencing of the endogenous CD81, which under these conditions 
would be induced by drug administration, yielding a significant decrease in 
locomotor activity as compared to controls. 
The role of the tetraspanin CD81 in drug addiction is not very surprising. 
Proteins of the tetraspanin superfamily are scaffold proteins, which 
participate in the formation of plasma membrane signalling complexes, 
regulate signal transduction and association with extracellular matrix. 
Growing evidence indicates that in the nervous system they enable synaptic 
adaptations and plasticity, which are key processes induced by the drug. 
Recent evidence implicates neuronal tetraspanins in axon growth and target 
recognition (Fradkin et al. 2002). CD81 regulates neuron-induced astrocyte 
cell-cycle exit (Kelic et al. 2001) and plays a central role in the dynamic 
regulation of complex formation between specific G-coupled protein receptor 
and their G-proteins (Little et al. 2004). CD9, a major molecular partner of 
CD81 (Charrin et al. 2001), forms extensive complexes with other 
tetraspanins, integrins and other proteins (Stipp et al. 2001), building the 
tetraspanin web beneath the plasma membranes (Terada et al. 2004). CD9 is a 
paranodal component regulating paranodal junctional formation in 
myelinated axons (Ishibashi et al. 2004) and is localized to neurons early in 
development, coincident with a period of active axon growth for many 
neuronal populations (Schmidt et al. 1996). Tetraspanins form complexes with 
integrins, mainly E1 integrins (Hemler 1998); these integrins are known to 
mediate axon growth induced by numerous extracellular matrix proteins. 
Enhanced integrin-mediated neurite outgrowth in response to CD9 activation 
suggests a functional relationship between integrins and tetraspanins 
(Banerjee et al. 1997). Furthermore integrin association to extracellular matrix 
proteins, e.g. laminin-5 is regulated by EWI-2 (Stipp et al. 2003), a major 
binding partner of CD81 (Stipp et al. 2001). Recent evidence suggests that 
tetraspanins may serve as a link between integrin subunits and various 
intracellular signalling molecules, such as phosphatidylinositol 4-kinase and 
PKC (Hemler 1998, Berditchevski et al. 1997). CD81 is also linked to 
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ERK/MAPK signalling (Carloni et al. 2004). Tetraspanin activation can also 
result in increases in intracellular calcium and enhanced tyrosine kinase and 
phosphatase activity (Carmo and Wright 1995), each of which has been 
implicated in the regulation of neurite outgrowth (Keynes and Cook 1995, 
Desai et al. 1997).
As drugs of abuse induce strong plasticity and molecular adaptations which 
underlie a complex rewiring of neural circuitry and results in the behaviours 
associated with addiction, it is not surprising that a scaffolding protein such 
as CD81 may play a role in these processes, as clearly shown in this study.  
Further studies will be devoted to clarify its function. 
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FIGURES
Figure 1. Drug Administration Protocols used in this study. Acute 
Treatment. Animals (n=6) were injected a single dose of cocaine (15 mg/kg) 
and sacrificed 24 h after injection. Binge Treatment. Animals (n=6) received 
four injections of high dose cocaine (30 mg/kg) and were sacrificed 24 h after 
the last injection. Chronic Treatment. Animals (n=6) received a single dose of 
cocaine (15 mg/kg) every day over 15 days and were sacrificed 24 h after the 
last injection. In each treatment (acute, binge or chronic), control animals 
were injected with saline solution under the same schedule.
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Figure 2. The Lentivirus vector-based RNA interference (Lenti-CD81-
shRNAs) construct. (A): Generation of a hairpin siRNA directed by a Pol III 
promoter. An inverted repeat is inserted at the +1 position of the U6 
promoter (-351 to +1). The individual motif is 19–25 nt, corresponding to the 
coding region of the gene of interest. The two motifs that form the inverted 
repeat are separated by a loop of §12 nt. The transcriptional termination 
signal of 5-6 Ts is added at the 3’ end of the inverted repeat. The resulting 
RNA is predicted to fold back to form a hairpin dsRNA. (B): Sequences of the 
CD81 targets used in this study. Sequences were adapted with a loop 
sequence to create siRNAs. The presumed transcription initiation site is 
located after the U6-specific sequence. Nucleotides that form the loop 
structure are indicated in green. The Pol III terminator is indicated in bold 
Target 1:  ATCCCTTGGAGAAAAGCCTTGTTCGGA C GTTCCGGATGCCAC    C GATATCGG   T GTATTCGGAACAGTTCCGTGTATTTTTCTCGA
Target 2:  ATCCCTTGGAGAAAAGCCTTGTT ACACC CCAGCCAGCCAGAAGGGGATATCGCGT  TTCTGGTTGGTTGGAGGTGTGGT TTTT TCTCGA
Target 3:  ATCCCTTGGAGAAAAGCCTTGTT  CA GGAGTGTTCCGGATGCCACCGAAGCTTGGTTGGTATTCGGAACAGTTCCGTGT TTTTTCTCGA
Target 4:  ATCCCTTGGAGAAAAGCCTTGTT GAC CCGAATACCACAACCGA GCTTGGTTGGCATCCGGAACAGCTCCGTGTT TTTTCTCGA
Target 5: ATCCCTTGGAGAAAAGCCTTGTT AG CACAACAGTTGAGCGTCTCATA AAG T GTA GAGACGCTTAATTGTTGTGGTT T TTCTCGA
U6-specific sequence     S nse         Loop     Antisense    TerminatorXho
loop terminator
MCS
Inducible
PromoterCMV R U5 cPPT CMV tTA PRE ²U3 R  U5U6
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black. (see materials and methods section for the exact position of each target 
within the CD81 sequence). 
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Figure 3. Cocaine-induced expression of CD81 mRNA. Real time 
quantitative-PCR analysis of CD81 mRNA expression changes from 
cocaine-treated or untreated rat brains. Animals (n=6) were administered 
cocaine or saline according to the different protocols described in figure 1. 
After sacrifice total RNA was extracted from the NAcc or the VTA and CD81 
mRNA was measured by means of quantitative RT-PCR. (A): mRNA levels 
in the nucleus accumbens; (B): mRNA levels in the ventral tegmental area.
Relative abundance of candidate transcripts is expressed relative to GAPDH 
from replicate determinations (as described in the “Materials and Methods”). 
After normalization, the ratios between samples from cocaine-treated and 
saline-treated tissues were calculated.  * p<0.05; ** p<0.01; *** p<0.001. 
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Figure 4. Expression of CD81 mRNA in HEK293T cells in vitro infected 
with Lenti-CD81 and Lenti-CD81-shRNAs: Quantification of CD81 mRNA 
levels was performed by means of real-time quantitative PCR (A & B) and 
immunohistochemistry (C & D) after HEK293T cells infection with Lenti-
CD81 or/and with different Lenti-CD81-shRNAs, either separately or all 
targets combined together. HEK293T cells were co-infected by both 
constructs expressing CD81 and CD81-specific shRNAs. After 48h, culture 
medium was removed, one part of the cells was used for total RNA 
extraction, cDNA preparation and quantitative real-time PCR. (A): Results 
from qRT-PCR after normalization against GAPDH and E-actin genes used as 
endogenous controls. Bars in the graphs represent means+SEM from 3 
independent experiments and RNA preparations. (B): PCR products were 
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verified by 2 % agarose gel electrophoresis and visualized with ethidium 
bromide staining. (C): Remaining cells were used for immunocytochemistry 
using a mouse histidine-tag antibody to check for CD81 protein expression. 
(D): The expression level of CD81 was then quantified after background 
substraction.
293T: HEK293T cells infected with Lenti-CD81 alone; GFP: HEK293T cells 
infected with Lenti-GFP alone; T 1-5: HEK293T cells co-infected with Lenti-
CD81 together with a single Lenti-CD81-shRNAs; All: HEK293T cells co-
infected with Lenti-CD81 together with all five Lenti-CD81-shRNAs. 
*p<0.001.
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Figure 5. in vivo silencing of endogenous CD81 in the VTA or NAcc with 
Lenti-CD81-shRNAs: quantification of endogenous CD81 transcripts by 
means of qRT-PCR. Lenti-CD81-shRNAs or Lenti-GFP (in control animals) 
were bilaterally injected into the VTA or into the NAcc. Seven days after 
operation, each animal was injected i.p. with 30 mg/kg cocaine-HCl every 2 h 
for 4 injections, following the “binge” protocol (figure 1). Control animals 
received 0.9 % saline injections under the same schedule. The rats were 
sacrificed by decapitation 24 h after the last injection. The VTA and the NAcc 
were dissected out and used for total RNA isolation, cDNA preparation and 
quantitative real-time PCR using CD81 specific oligos. Results were 
normalized against GAPDH and E-actin genes used as endogenous controls. 
VTA: Ventral Tegmentum Area; NAcc: Nucleus Accumbens; GFP: animals 
injected with Lenti-GFP; shRNAs: animals injected with Lenti-CD81-shRNAs. 
*p<0.001.
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Figure 6. Effects of CD81 silencing in vivo on Cocaine-induced Behavioural 
changes. CD81 and CD81-shRNAs expression in the NAcc or VTA: 
Locomotor activity monitoring. Lenti-CD81 alone or Lenti-CD81 together 
with both Lenti-CD81-shRNA-3 and -5 were bilaterally injected into the NAcc 
(Panel A) or in the VTA (Panel B)(n=6). Control animals (n=6) were 
bilaterally injected with Lenti-GFP alone or Lenti-GFP together with Lenti-sh-
RNA-3 and –5. Seven days after operation, session A (no doxycycline) was 
initiated and animals were chronically administered 15 mg/kg cocaine each 
day. Prior to daily cocaine injection, each animal was placed in the 
monitoring cage for 30 min until stable basal activity was measured. Cocaine 
(15 mg/kg, i.p.) was then injected (Arrow) and the animal returned to the 
cage for 60 min while locomotor activity monitoring was conducted. Each 
data point represents the average over 3 animals generated in each session. 
Peak intensities of the locomotor activity measured at 45 min from the 
panels in A and B. Panel C corresponds to the peak intensities in the NAcc. 
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Panel D corresponds to the peak intensities in the VTA. Each data point 
represents the average over 3 animals. Bars in the graphs represent 
means+SEM.
NAcc: Nucleus Accumbens; VTA: Ventral Tegmentum Area; CD81: animals 
injected with Lenti-CD81; CD81 & shRNA: animals co-injected with Lenti-
CD81 and Lenti-CD81-shRNAs; GFP & shRNA: animals co-injected with 
Lenti-GFP and Lenti-CD81-shRNAs; GFP: animals injected with Lenti-GFP. 
* p<0.001; ** p<0.05; *** p<0.08. 
Figure 7: Immunohistochemistry of CD81 after in vivo transfer of Lenti-
CD81 with or without Lenti-CD81-shRNAs into the NAcc ((Panel A and B)
and into the VTA (Panel C and D): 2 Pl of Lenti-CD81 were injected into the 
NAcc or VTA with and without 2 Pl of Lenti-CD81-shRNAs (coordinates: see 
Material and Methods). Animals were given either 5 % sucrose (Panel A and 
C) or 5 % sucrose supplemented with 0.02 % doxycycline (Panel B and D).
Animals were sacrificed before addition of doxycycline, (left panels) and at 
the end of the doxcycycline period (right panels) and immunohistochemistry
was performed (see Methods). Slides were visualized with either 10X or 63X 
magnification.
